Serum syndecan-1 in patients with newly diagnosed monoclonal proteinemia.
Serum syndecan-1 was investigated in 189 patients with newly diagnosed monoclonal proteinemia [the diagnoses were multiple myeloma (66), monoclonal gammopathies of undetermined significance (MGUS; n=54), provisional MGUS (no bone marrow examination performed; n=69)] and 36 controls. Syndecan-1 levels ranged widely between all diagnostic categories and were of limited discriminatory value (sensitivity 68%, specificity 78%) in patients with newly diagnosed monoclonal proteinemia.
Schaar
Cees G
CG
Vermeer
Henricus J
HJ
Wijermans
Pierre W
PW
Huisman
Wim
W
le Cessie
Saskia
S
Kluin-Nelemans
Hanneke C
HC
D005500:Follow-Up Studies; D006801:Humans; D008562:Membrane Glycoproteins / Q000097:blood*; D009101:Multiple Myeloma / Q000097:blood* / Q000175:diagnosis*; D011509:Proteoglycans / Q000097:blood*; D012680:Sensitivity and Specificity; D015996:Survival Rate; D053668:Syndecan-1; D053667:Syndecans
D008562:Membrane Glycoproteins; D011509:Proteoglycans; C508241:SDC1 protein, human; D053668:Syndecan-1; D053667:Syndecans